Colleen Nofi

78 timestamped statements across 3 collections — auto-found in recorded discussions, each timestamp jumps to the exact moment.

Etiologies (Gastroschisis/NEC/Atresia/Volvulus) · guest expert Intestinal Rehab · guest expert

Featured diaries

Ep 63 · 5:22
When we compared overall survival of murine pups subjected to the neck model, we found a significant improvement in survival, up to 80% in pups treated with MP3, compared to only 50% for vehicle treated pups.
Ep 94 · 5:22
When we compared overall survival of murine pups subjected to the neck model, we found a significant improvement in survival, up to 80% in pups treated with MP3, compared to only 50% for vehicle treated pups.
Ep 16 · 5:22
When we compared overall survival of murine pups subjected to the neck model, we found a significant improvement in survival, up to 80% in pups treated with MP3, compared to only 50% for vehicle treated pups.
Ep 63 · 0:39
Necrotizing entercolitis or neck is a devastating gastrointestinal disease impacting premature infants whose pathophysiology is driven by a multitude of complex pathways that are not completely understood.
Ep 94 · 0:39
Necrotizing entercolitis or neck is a devastating gastrointestinal disease impacting premature infants whose pathophysiology is driven by a multitude of complex pathways that are not completely understood.
Ep 16 · 0:39
Necrotizing entercolitis or neck is a devastating gastrointestinal disease impacting premature infants whose pathophysiology is driven by a multitude of complex pathways that are not completely understood.

Nothing matches these filters — clear the search or widen the filters.

Dr. Colleen Nofi - Best of the Best in Pediatric Surgery 2025

Ep 63 · 0:39
quote Necrotizing entercolitis or neck is a devastating gastrointestinal disease impacting premature infants whose pathophysiology is driven by a multitude of complex pathways that are not completely understood.
Ep 63 · 0:39
clinical Necrotizing enterocolitis is a devastating gastrointestinal disease impacting premature infants whose pathophysiology is driven by complex pathways that are not completely understood
Ep 63 · 0:52
clinical NEC has limited treatment options and an unacceptably high morbidity and mortality risk
Ep 63 · 1:06
clinical Under biologic conditions, CIRP is found inside the cell where it acts as an RNA chaperone protein
Ep 63 · 1:12
clinical In states of cellular stress such as sepsis, CIRP escapes outside the cell
Ep 63 · 1:19
quote Once released from the cell, CRP becomes extracellular CIRP or ECIRP, where it then acts as a damp by enhancing the release of cytokines and chemokines, and amplifying the inflammatory cascade.
Ep 63 · 1:19
clinical Once released from the cell, extracellular CIRP acts as a DAMP by enhancing the release of cytokines and chemokines and amplifying the inflammatory cascade
Ep 63 · 1:33
clinical MOP3 (MFGE8 derived oligopeptide 3) is an eCIRP scavenging peptide that removes eCIRP from circulation to reduce inflammation
Ep 63 · 2:30
clinical CIRP knockout protected pups from NEC severity with preservation of intestinal villi architecture
Ep 63 · 2:59
clinical CIRP knockout mice subjected to NEC showed reduced intestinal inflammation as measured by mRNA levels of IL-6 and TNF-alpha in the small bowel
Ep 63 · 3:36
clinical CIRP knockout pups had reduced fluorescent dextran leakage indicating preserved intestinal barrier function compared to wild-type NEC pups
Ep 63 · 3:57
clinical CIRP knockout pups subjected to NEC had 100% survival whereas wild-type pups had only 65% survival in the same model under the same conditions
Ep 63 · 3:57
quote Remarkably, in the same model under the same conditions, there was 100% survival for CRP knockout pups subjected to neck, whereas the survival was only 65% for wild type pups.
Ep 63 · 4:18
clinical MOP3 treatment reduced circulating eCIRP levels in NEC pups compared to vehicle
Ep 63 · 4:27
clinical Reduction in eCIRP with MOP3 treatment correlated with reduction in systemic inflammatory markers including IL-6 and TNF-alpha
Ep 63 · 4:37
clinical MOP3 treatment protected against NEC severity with preservation of intestinal villi
Ep 63 · 4:55
clinical MOP3 treatment reduced intestinal inflammation in NEC as measured by mRNA levels of IL-6 and TNF-alpha
Ep 63 · 5:05
clinical MOP3-treated pups had significantly reduced fluorescence intensity indicating protection of the intestinal barrier compared to vehicle-treated NEC pups
Ep 63 · 5:22
clinical Murine pups subjected to NEC and treated with MOP3 had 80% survival compared to only 50% survival in vehicle-treated pups
Ep 63 · 5:22
quote When we compared overall survival of murine pups subjected to the neck model, we found a significant improvement in survival, up to 80% in pups treated with MP3, compared to only 50% for vehicle treated pups.
Ep 63 · 5:42
clinical MOP3 protects against NEC pathogenesis by scavenging eCIRP and preventing deleterious downstream impacts
Ep 63 · 5:42
clinical eCIRP exacerbates NEC pathogenesis by increasing inflammation and intestinal injury
Ep 63 · 6:53
clinical MOP3 is effective in other models of ischemia-reperfusion injury in the gut
Ep 63 · 7:00
clinical The therapeutic benefit of MOP3 is not at the same level as complete CIRP knockdown
Ep 63 · 7:34
clinical The murine NEC model uses a 4-day protocol with continuous stressors including LPS, formula gavage, and hypoxia
Ep 63 · 7:49
clinical MOP3 treatment was administered once per day at the beginning of the model, ongoing with the NEC insult
Intestinal Rehab 26 entries

Dr. Colleen Nofi - Best of the Best in Pediatric Surgery 2025

Ep 94 · 0:39
quote Necrotizing entercolitis or neck is a devastating gastrointestinal disease impacting premature infants whose pathophysiology is driven by a multitude of complex pathways that are not completely understood.
Ep 94 · 0:39
clinical Necrotizing enterocolitis is a devastating gastrointestinal disease impacting premature infants whose pathophysiology is driven by complex pathways that are not completely understood
Ep 94 · 0:52
clinical NEC has limited treatment options and an unacceptably high morbidity and mortality risk
Ep 94 · 1:06
clinical Under biologic conditions, CIRP is found inside the cell where it acts as an RNA chaperone protein
Ep 94 · 1:12
clinical In states of cellular stress such as sepsis, CIRP escapes outside the cell
Ep 94 · 1:19
clinical Once released from the cell, extracellular CIRP acts as a DAMP by enhancing the release of cytokines and chemokines and amplifying the inflammatory cascade
Ep 94 · 1:19
quote Once released from the cell, CRP becomes extracellular CIRP or ECIRP, where it then acts as a damp by enhancing the release of cytokines and chemokines, and amplifying the inflammatory cascade.
Ep 94 · 1:33
clinical MOP3 (MFGE8 derived oligopeptide 3) is an eCIRP scavenging peptide that removes eCIRP from circulation to reduce inflammation
Ep 94 · 2:30
clinical CIRP knockout protected pups from NEC severity with preservation of intestinal villi architecture
Ep 94 · 2:59
clinical CIRP knockout mice subjected to NEC showed reduced intestinal inflammation as measured by mRNA levels of IL-6 and TNF-alpha in the small bowel
Ep 94 · 3:36
clinical CIRP knockout pups had reduced fluorescent dextran leakage indicating preserved intestinal barrier function compared to wild-type NEC pups
Ep 94 · 3:57
clinical CIRP knockout pups subjected to NEC had 100% survival whereas wild-type pups had only 65% survival in the same model under the same conditions
Ep 94 · 3:57
quote Remarkably, in the same model under the same conditions, there was 100% survival for CRP knockout pups subjected to neck, whereas the survival was only 65% for wild type pups.
Ep 94 · 4:18
clinical MOP3 treatment reduced circulating eCIRP levels in NEC pups compared to vehicle
Ep 94 · 4:27
clinical Reduction in eCIRP with MOP3 treatment correlated with reduction in systemic inflammatory markers including IL-6 and TNF-alpha
Ep 94 · 4:37
clinical MOP3 treatment protected against NEC severity with preservation of intestinal villi
Ep 94 · 4:55
clinical MOP3 treatment reduced intestinal inflammation in NEC as measured by mRNA levels of IL-6 and TNF-alpha
Ep 94 · 5:05
clinical MOP3-treated pups had significantly reduced fluorescence intensity indicating protection of the intestinal barrier compared to vehicle-treated NEC pups
Ep 94 · 5:22
clinical Murine pups subjected to NEC and treated with MOP3 had 80% survival compared to only 50% survival in vehicle-treated pups
Ep 94 · 5:22
quote When we compared overall survival of murine pups subjected to the neck model, we found a significant improvement in survival, up to 80% in pups treated with MP3, compared to only 50% for vehicle treated pups.
Ep 94 · 5:42
clinical MOP3 protects against NEC pathogenesis by scavenging eCIRP and preventing deleterious downstream impacts
Ep 94 · 5:42
clinical eCIRP exacerbates NEC pathogenesis by increasing inflammation and intestinal injury
Ep 94 · 6:53
clinical MOP3 is effective in other models of ischemia-reperfusion injury in the gut
Ep 94 · 7:00
clinical The therapeutic benefit of MOP3 is not at the same level as complete CIRP knockdown
Ep 94 · 7:34
clinical The murine NEC model uses a 4-day protocol with continuous stressors including LPS, formula gavage, and hypoxia
Ep 94 · 7:49
clinical MOP3 treatment was administered once per day at the beginning of the model, ongoing with the NEC insult

Dr. Colleen Nofi - Best of the Best in Pediatric Surgery 2025

Ep 16 · 0:39
clinical Necrotizing enterocolitis is a devastating gastrointestinal disease impacting premature infants whose pathophysiology is driven by complex pathways that are not completely understood
Ep 16 · 0:39
quote Necrotizing entercolitis or neck is a devastating gastrointestinal disease impacting premature infants whose pathophysiology is driven by a multitude of complex pathways that are not completely understood.
Ep 16 · 0:52
clinical NEC has limited treatment options and an unacceptably high morbidity and mortality risk
Ep 16 · 1:06
clinical Under biologic conditions, CIRP is found inside the cell where it acts as an RNA chaperone protein
Ep 16 · 1:12
clinical In states of cellular stress such as sepsis, CIRP escapes outside the cell
Ep 16 · 1:19
clinical Once released from the cell, extracellular CIRP acts as a DAMP by enhancing the release of cytokines and chemokines and amplifying the inflammatory cascade
Ep 16 · 1:19
quote Once released from the cell, CRP becomes extracellular CIRP or ECIRP, where it then acts as a damp by enhancing the release of cytokines and chemokines, and amplifying the inflammatory cascade.
Ep 16 · 1:33
clinical MOP3 (MFGE8 derived oligopeptide 3) is an eCIRP scavenging peptide that removes eCIRP from circulation to reduce inflammation
Ep 16 · 2:30
clinical CIRP knockout protected pups from NEC severity with preservation of intestinal villi architecture
Ep 16 · 2:59
clinical CIRP knockout mice subjected to NEC showed reduced intestinal inflammation as measured by mRNA levels of IL-6 and TNF-alpha in the small bowel
Ep 16 · 3:36
clinical CIRP knockout pups had reduced fluorescent dextran leakage indicating preserved intestinal barrier function compared to wild-type NEC pups
Ep 16 · 3:57
clinical CIRP knockout pups subjected to NEC had 100% survival whereas wild-type pups had only 65% survival in the same model under the same conditions
Ep 16 · 3:57
quote Remarkably, in the same model under the same conditions, there was 100% survival for CRP knockout pups subjected to neck, whereas the survival was only 65% for wild type pups.
Ep 16 · 4:18
clinical MOP3 treatment reduced circulating eCIRP levels in NEC pups compared to vehicle
Ep 16 · 4:27
clinical Reduction in eCIRP with MOP3 treatment correlated with reduction in systemic inflammatory markers including IL-6 and TNF-alpha
Ep 16 · 4:37
clinical MOP3 treatment protected against NEC severity with preservation of intestinal villi
Ep 16 · 4:55
clinical MOP3 treatment reduced intestinal inflammation in NEC as measured by mRNA levels of IL-6 and TNF-alpha
Ep 16 · 5:05
clinical MOP3-treated pups had significantly reduced fluorescence intensity indicating protection of the intestinal barrier compared to vehicle-treated NEC pups
Ep 16 · 5:22
quote When we compared overall survival of murine pups subjected to the neck model, we found a significant improvement in survival, up to 80% in pups treated with MP3, compared to only 50% for vehicle treated pups.
Ep 16 · 5:22
clinical Murine pups subjected to NEC and treated with MOP3 had 80% survival compared to only 50% survival in vehicle-treated pups
Ep 16 · 5:42
clinical MOP3 protects against NEC pathogenesis by scavenging eCIRP and preventing deleterious downstream impacts
Ep 16 · 5:42
clinical eCIRP exacerbates NEC pathogenesis by increasing inflammation and intestinal injury
Ep 16 · 6:53
clinical MOP3 is effective in other models of ischemia-reperfusion injury in the gut
Ep 16 · 7:00
clinical The therapeutic benefit of MOP3 is not at the same level as complete CIRP knockdown
Ep 16 · 7:34
clinical The murine NEC model uses a 4-day protocol with continuous stressors including LPS, formula gavage, and hypoxia
Ep 16 · 7:49
clinical MOP3 treatment was administered once per day at the beginning of the model, ongoing with the NEC insult